Come online and join Shares and AJ Bell Media at their next webinar on Wednesday 3 June 2020 which can be accessed from wherever you are!
Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for you to ask questions. This is your chance to hear first-hand from the people making the decisions on what these companies do and how they are going to generate shareholder value.
Accessing the webinar is very simple; simply register your details and follow the link that you will receive in your confirmation email at the scheduled time of the webinar.
The webinar will not require your participation in the form of audio or video, however you will have the opportunity to ask questions to the presenters via an online chat window during the webinar.
The webinar will follow a similar format to our regular Shares Investor Evenings, and is open to any existing shareholders or potential investors.
The webinar will feature the following companies:
Open Orphan (ORPH) goal is to become Europes leading rare disease and orphan drug focused pharma services company. Its management team have extensive industry and financial expertise.
Shield Therapeutics (STX) is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.
Silence Therapeutics (SLN) is a biotechnology company in the United Kingdom. It uses its RNA technology to develop drugs to address genetic disorders.
Click on the REGISTER tab now to secure your place!
Who Should Attend
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Evening timings
18.00
Introduction
Roland Spencer, Head of Corporate Development - Shares
18.05
Shield Therapeutics
Tim Watts, CEO - Shield Therapeutics (STX)
18.30
Open Orphan
Cathal Friel, Executive Chairman - Open Orphan (ORPH)
18.55
Silence Therapeutics
Dr. Rob Quinn, CFO - Silence Therapeutics (SLN)
19.20
End of event